ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They currently have a $30.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd.

ImmunityBio Stock Down 1.9 %

IBRX stock opened at $2.62 on Friday. The business’s 50-day moving average price is $4.49 and its 200-day moving average price is $4.74. The stock has a market cap of $1.83 billion, a P/E ratio of -2.85 and a beta of 0.86. ImmunityBio has a twelve month low of $2.61 and a twelve month high of $10.53.

Hedge Funds Weigh In On ImmunityBio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. increased its position in shares of ImmunityBio by 16.0% during the 2nd quarter. Victory Capital Management Inc. now owns 19,953 shares of the company’s stock valued at $126,000 after purchasing an additional 2,746 shares during the last quarter. Wealth Effects LLC boosted its stake in ImmunityBio by 3.4% during the third quarter. Wealth Effects LLC now owns 90,500 shares of the company’s stock worth $337,000 after buying an additional 3,000 shares during the period. Exchange Traded Concepts LLC increased its position in ImmunityBio by 8.4% during the third quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company’s stock valued at $178,000 after acquiring an additional 3,722 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of ImmunityBio by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after acquiring an additional 4,545 shares during the period. Finally, Courier Capital LLC lifted its holdings in shares of ImmunityBio by 50.0% in the 3rd quarter. Courier Capital LLC now owns 30,000 shares of the company’s stock worth $112,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.